Herceptin 150mg Vial is used for the following:
1.1 Adjuvant Breast Cancer
Herceptin 150mg Vial is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1)]) breast cancer
as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
with docetaxel and carboplatin
as a single agent following multi-modality anthracycline based therapy.
1.2 Metastatic Breast Cancer
Herceptin 150mg Vial is indicated:
In combination with paclitaxel for first‑line treatment of HER2‑overexpressing metastatic breast cancer
As a single agent for treatment of HER2‑overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
1.3 Metastatic Gastric Cancer
Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.
Herceptin 150mg Vial is used for the following:
1.1 Adjuvant Breast Cancer
Herceptin 150mg Vial is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1)]) breast cancer
as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
with docetaxel and carboplatin
as a single agent following multi-modality anthracycline based therapy.
1.2 Metastatic Breast Cancer
Herceptin 150mg Vial is indicated:
In combination with paclitaxel for first‑line treatment of HER2‑overexpressing metastatic breast cancer
As a single agent for treatment of HER2‑overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
1.3 Metastatic Gastric Cancer
Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.